In the last trading session, 1.31 million Mesoblast Ltd ADR (NASDAQ:MESO) shares changed hands as the company’s beta touched 3.41. With the company’s per share price at $16.98 changed hands at -$0.2 or -1.16% during last session, the market valuation stood at $1.97B. MESO’s last price was a discount, traded about -29.56% off its 52-week high of $22.00. The share price had its 52-week low at $1.61, which suggests the last value was 90.52% up since then. When we look at Mesoblast Ltd ADR’s average trading volume, we note the 10-day average is 0.49 million shares, with the 3-month average coming to 388.17K.
Analysts gave the Mesoblast Ltd ADR (MESO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 2 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended MESO as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Mesoblast Ltd ADR’s EPS for the current quarter is expected to be 0.
Mesoblast Ltd ADR (NASDAQ:MESO) trade information
Instantly MESO was in red as seen at the end of in last trading. With action -17.61%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -14.24%, with the 5-day performance at -17.61% in the red. However, in the 30-day time frame, Mesoblast Ltd ADR (NASDAQ:MESO) is 56.64% up. Looking at the short shares, we see there were 1.8 million shares sold at short interest cover period of 2.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11.5, meaning bulls need a downside of -47.65% from its current market value. According to analyst projections, MESO’s forecast low is 11 with 12 as the target high. To hit the forecast high, the stock’s price needs a 29.33% surge from its current level, while the stock would need to tank 35.22% for it to hit the projected low.
Mesoblast Ltd ADR (MESO) estimates and forecasts
Data shows that the Mesoblast Ltd ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 127.61% over the past 6 months, a 16.85% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 847.04% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 1.19M. 2 analysts are of the opinion that Mesoblast Ltd ADR’s revenue for the current quarter will be 3.38M. The estimates for the next quarter sales put growth at -35.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.34%. The 2025 estimates are for Mesoblast Ltd ADR earnings to increase by 42.65%.
MESO Dividends
Mesoblast Ltd ADR is expected to release its next quarterly earnings report in February.
SUMMIT X, LLC holds the second largest percentage of outstanding shares, with 0.1497% or 0.15 million shares worth $1.01 million as of 2024-06-30.
Among Mutual Funds, the top two as of Aug 31, 2024 were Trust for Professional Managers-ActivePassive International Equity ETF and Advisors Preferred Tr-Quantified Global Fund . With 46.53 shares estimated at $0.79 million under it, the former controlled 0.04% of total outstanding shares. On the other hand, Advisors Preferred Tr-Quantified Global Fund held about 0.01% of the shares, roughly 6.4 shares worth around $0.11 million.
